Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
| (Q6)Sep 30, 2025 | (FY)Mar 31, 2025 | (Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | ||||||||||
| Earning before tax | ---- | -116.50%-7.06M | ---- | 125.97%42.78M | ---- | 521.18%18.93M | ---- | 30.22%-4.5M | ---- | 80.27%-6.44M |
| Profit adjustment | ||||||||||
| Interest (income) - adjustment | ---- | -47.41%-3.59M | ---- | -514.14%-2.43M | ---- | -2,946.15%-396K | ---- | 77.59%-13K | ---- | 90.63%-58K |
| Impairment and provisions: | ---- | 17,636.54%9.22M | ---- | 100.35%52K | ---- | -1,561.13%-14.77M | ---- | -91.29%1.01M | ---- | 292.36%11.61M |
| -Impairment of trade receivables (reversal) | ---- | 3,555.41%5.41M | ---- | 100.94%148K | ---- | ---15.81M | ---- | ---- | ---- | ---- |
| -Other impairments and provisions | ---- | 4,071.88%3.81M | ---- | -109.22%-96K | ---- | 2.97%1.04M | ---- | -91.29%1.01M | ---- | 292.36%11.61M |
| Asset sale loss (gain): | ---- | 61.54%-10K | ---- | 36.59%-26K | ---- | 50.60%-41K | ---- | 18.63%-83K | ---- | ---102K |
| -Loss (gain) on sale of property, machinery and equipment | ---- | 61.54%-10K | ---- | 36.59%-26K | ---- | 50.60%-41K | ---- | 18.63%-83K | ---- | ---102K |
| Depreciation and amortization: | ---- | 13.06%7.7M | ---- | 5.83%6.81M | ---- | 7.79%6.43M | ---- | -22.70%5.97M | ---- | 7.48%7.72M |
| Financial expense | ---- | --30K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Operating profit before the change of operating capital | ---- | -86.95%6.16M | ---- | 364.62%47.18M | ---- | 325.43%10.16M | ---- | -81.25%2.39M | ---- | 155.04%12.73M |
| Change of operating capital | ||||||||||
| Accounts receivable (increase)decrease | ---- | 20.80%-10.07M | ---- | -136.33%-12.71M | ---- | 173.66%34.98M | ---- | -1,275.93%-47.5M | ---- | -134.80%-3.45M |
| Accounts payable increase (decrease) | ---- | 140.88%13.26M | ---- | -489.04%-32.43M | ---- | -76.45%8.34M | ---- | 1,949.22%35.39M | ---- | 77.48%-1.91M |
| Financial assets at fair value (increase)decrease | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 200.00%2.27M |
| Special items for working capital changes | ---- | -119.17%-8.99M | ---- | 364.01%46.86M | ---- | -52.04%-17.75M | ---- | -1,288.11%-11.67M | ---- | -112.44%-841K |
| Cash from business operations | ---- | -99.26%363K | ---- | 36.86%48.9M | ---- | 267.03%35.73M | ---- | -343.12%-21.39M | ---- | 151.08%8.8M |
| Other taxs | ---- | ---2.16M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --753K |
| Special items of business | -20.09%-6.81M | ---- | -129.21%-5.67M | ---- | -21.84%19.41M | ---- | 606.16%24.83M | ---- | ---4.91M | ---- |
| Net cash from operations | -20.09%-6.81M | -103.68%-1.8M | -129.21%-5.67M | 36.86%48.9M | -21.84%19.41M | 267.03%35.73M | 606.16%24.83M | -323.96%-21.39M | -152.22%-4.91M | 155.45%9.55M |
| Cash flow from investment activities | ||||||||||
| Interest received - investment | -38.51%859K | 58.33%3.25M | 124.60%1.4M | 1,160.12%2.05M | 2,121.43%622K | 1,153.85%163K | 600.00%28K | -77.59%13K | -91.11%4K | -90.63%58K |
| Decrease in deposits (increase) | -5,671.59%-5.08M | ---- | 50.84%-88K | ---- | 95.69%-179K | 100,350.00%2.01M | ---4.15M | 99.90%-2K | ---- | -170.80%-2M |
| Sale of fixed assets | --13K | -61.54%10K | ---- | -36.59%26K | --26K | -97.95%41K | ---- | 1,860.78%2M | 69,900.00%1.4M | --102K |
| Purchase of fixed assets | 38.48%-4.17M | -300.61%-10.5M | -535.02%-6.78M | 70.40%-2.62M | 81.53%-1.07M | -261.13%-8.86M | -176.78%-5.78M | 73.83%-2.45M | 58.72%-2.09M | 19.68%-9.37M |
| Other items in the investment business | ---- | --1.2M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash from investment operations | -53.10%-8.38M | -1,016.08%-6.04M | -813.69%-5.47M | 91.86%-541K | 93.95%-599K | -1,407.03%-6.65M | -1,346.28%-9.91M | 96.07%-441K | 93.16%-685K | -36.47%-11.21M |
| Net cash before financing | -36.30%-15.19M | -116.21%-7.84M | -159.24%-11.14M | 66.28%48.36M | 26.03%18.81M | 233.21%29.08M | 366.95%14.93M | -1,215.12%-21.83M | -804.69%-5.59M | 93.47%-1.66M |
| Cash flow from financing activities | ||||||||||
| Interest paid - financing | ---15K | ---30K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash from financing operations | -200.00%-237K | ---316K | ---79K | ---- | ---- | ---- | ---- | ---- | ---- | 93.80%-67K |
| Net Cash | -37.45%-15.43M | -116.86%-8.15M | -159.66%-11.22M | 66.28%48.36M | 26.03%18.81M | 233.21%29.08M | 366.95%14.93M | -1,164.10%-21.83M | -712.65%-5.59M | 93.49%-1.73M |
| Begining period cash | -8.73%85.24M | 107.36%93.4M | 107.36%93.4M | 182.22%45.04M | 182.22%45.04M | -57.77%15.96M | -57.77%15.96M | -4.37%37.79M | -4.37%37.79M | -40.16%39.52M |
| Cash at the end | -15.04%69.82M | -8.73%85.24M | 28.70%82.17M | 107.36%93.4M | 106.74%63.85M | 182.22%45.04M | -4.08%30.88M | -57.77%15.96M | -17.07%32.2M | -4.37%37.79M |
| Cash balance analysis | ||||||||||
| Bank deposits | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -0.10%-2.01M | ---2M | ---2M |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | National Health Accounting Firm Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.